Retail attention on LQDA has spiked 4.5 standard deviations above its own 90-day history, per Wikipedia views and ORTEX stock page traffic as of 27 September. That surge in eyeballs coincides with a stock that has climbed roughly 3% over the past week and 4.4% over the past month. At the same time, short sellers are adding positions at a steady clip, and options traders are betting heavily on further gains.
Short interest stands at 15.6% of free float as of 29 September, up 10.1% over the past week and nearly 20% over the past month. That is a meaningful and rising position. Yet options traders are pointing the other way. The put-call ratio sits at 0.32, against a 20-day mean of 0.38. Calls dominate the open interest by a wide margin.
The ORTEX short score is 71, placing LQDA in the 11th percentile for short score rank across the market. That is an elevated reading, reflecting the weight of the short positioning.
Despite the shorts building, the lending market is not stressed. Availability sits at 325%, meaning roughly three shares are available to borrow for every one already lent out. That compares with a 52-week low availability of 124%. Cost to borrow has fallen sharply, down 48% week-on-week to 0.29%. Short sellers are adding, but they are not competing fiercely for supply.
Director Raman Singh sold shares on 11 and 14 September, with open-market sales totalling approximately $1.18 million. Both transactions were logged as discretionary, with no 10b5-1 plan disclosed. These were exercise-and-sell transactions: Singh exercised options at roughly $9.31 per share and sold the resulting stock at market prices near $66 to $69. The net economics reflect compensation liquidation rather than a directional bet against the company.
Broader insider flow over the past 90 days shows net sales of approximately $48.8 million across 622,000 shares, though much of that reflects Chief Business Officer Jason Adair's large 10b5-1 plan sales in August.
BlackRock holds 12.1% of shares as of August 2026, having added 5.3 million shares in its most recent reported period. State Street added 1.1 million shares. Farallon Capital holds 9.3% and Caligan Partners 9.1%, both as last reported at June 2026. No 13D activist is on the register.
Analyst consensus remains constructive. Wells Fargo raised its target to $108, Needham to $110, and BTIG to $111 following August earnings, all maintaining positive ratings. The consensus mean target stands at $107.75 against a current price of $70.69. Next earnings are scheduled for 5 November 2026.
See the live data behind this article on ORTEX.
Open LQDA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
